The associations of genetically proxied LDL receptor (LDLR) mediated LDL-c and the genetically proxied levels of circulating LDL-c on prostate cancer outcomes were also examined to assess whether evidence of the findings for inhibiting drug targets may be generalisable to the lowering of LDL-c. The gene discussed is LDLR; the disease is prostate cancer.